Drug Development
IN-HOUSE RD PROJECTS
Bio-Betters Drugs are new drugs designed from existing ones with improved properties such as higher efficacy, selectivity, stability, half-life, and/or lower toxicity/immunogenicity. The projects are subject to adjustment according to validation outcomes and market competitiveness.
Projects
Super Agonist Antibody Platform
AgTa-101
(Bio-Better)
AgTa-106
(Bio-Better)
AgTa-234
(Bio-Better)
AgTa-203
(Bio-Better)
Diseases
(Platform)
Immune Diseases
Cardiovascular Diseases
Tumors
Liver Tumor
Current Status
Validating with AI and in vitro testing.
Optimizing the candidates with AI and validating in wet-lab.
Optimizing the candidates with AI and validating in wet-lab.
Optimizing the candidates with AI and validating in wet-lab.
Optimizing the candidates with AI and validating in wet-lab.
Projects
Super Agonist Antibody Platform
AgTa-279 (Bio-Better Agonist Ab)
AgTa-301 (Cyclic peptide)
AgTa-101 (Bio-Better Agonist Ab)
AgTa-274 (Cyclic Peptide)
AgTa-215 (Cyclic Peptide)
Diseases
(Platform)
Rheumatoid Arthritis
Fibrosis
IBD (UC & Crohn’s)
Cancers
Cancers
Current Status
Validating with AI and In-Vitro testing
Optimizing lead candidates with AI and testing in vitro/vivo disease models
Selecting the best candidates with AI and testing in vitro/vivo disease models
Optimizing lead candidates with AI and testing in vitro/vivo disease models
Selecting the best candidates with AI and testing in vitro/vivo disease models
Visibility AI-modeling study is on-going
Estimated Completion Date
Q2 2027
Q4 2027
Q2 2028
Q4 2028
Q2 2029
